Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track APVO with free AI briefings, catalyst countdowns, and dilution alerts.

APVO · Aptevo Therapeutics Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$9.8M Cash on Hand
4.4mo Cash Runway
Follow APVO by email Get an email when APVO reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about APVO, unsubscribe in one click. Privacy

📣 What APVO Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Anti-4-1BB/5T4 Bispecific Antibody ALG.APV-527 Solid Tumor Phase 1/2 · NCT05934539 Unknown
Otlertuzumab (TRU-016) Chronic Lymphocytic Leukemia (CLL) Phase 1/2 · NCT01188681 Completed
Bendamustine Chronic Lymphocytic Leukemia (CLL) Phase 1/2 · NCT01188681 Completed
Idelalisib Chronic Lymphocytic Leukemia Phase 1 · NCT01644253 Terminated
ES414 Prostate Cancer Phase 1 · NCT02262910 Completed
Mipletamig (APVO436) Acute Myeloid Leukemia (AML) Phase 1 · NCT06634394 Recruiting
APVO210 Psoriasis Phase 1 · NCT03768219 Terminated

Also used in these trials (approved or third-party drugs, not APVO's own candidates): Venetoclax, Rituximab, Azacitidine.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

APVO holds $9.8M in cash and short-term investments (as of Jun 30, 2026) and burns about $6.7M/quarter from operations, an estimated runway of 4.4 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 70 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when APVO files for a raise →

👥 Who Owns APVO

Insiders 3% Institutions (9 holders) 2.2% Public and other holders 94.8%
HolderTypeShares% of sharesAs of
NIOWAVE, INC.
10% owner
Insider 98,522 2.84% 2026-05-25
Marvin L White
Executive Chair, Director
Insider 1,261 0.04% 2026-07-17
Grady III Grant
Director
Insider 1,150 0.03% 2026-08-06
Jeffrey G. Lamothe
President and CEO, Director
Insider 961 0.03% 2026-08-06
SoYoung Kwon
SVP, GC, BD & Corp Affairs
Insider 638 0.02% 2026-08-06
Daphne Taylor
SVP, CFO
Insider 638 0.02% 2026-08-06
Dirk Huebner
SVP, CMO
Insider 482 0.01% 2026-08-06
Zsolt Harsanyi
Director
Insider 400 0.01% 2026-08-06
Barbara Lopez Kunz
Director
Insider 400 0.01% 2026-08-06
Daniel Abdun-Nabi
Director
Insider 400 0.01% 2026-08-06
John Niederhuber
Director
Insider 400 0.01% 2026-08-06
BANK OF AMERICA CORP /DE/
10% owner
Insider 27 0.00% 2025-09-30

Share count 3,464,923 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full APVO picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for APVO and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.